Pregled bibliografske jedinice broj: 666258
Side effects of antipsychotic medication: metabolic syndrome and serotonergic receptors gene polymorphisms
Side effects of antipsychotic medication: metabolic syndrome and serotonergic receptors gene polymorphisms // Periodicum Biologorum / Vitale, Branko (ur.).
Zagreb, 2013. str. 60-60 (poster, domaća recenzija, sažetak, ostalo)
CROSBI ID: 666258 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Side effects of antipsychotic medication: metabolic syndrome and serotonergic receptors gene polymorphisms
Autori
Mustapić, Maja ; Pivac, Nela ; Kozumplik, Oliver ; Uzun, Suzana ; Muck-Šeler, Dorotea
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Periodicum Biologorum
/ Vitale, Branko - Zagreb, 2013, 60-60
Skup
7. Hrvatski kongres farmakologije
Mjesto i datum
Zagreb, Hrvatska, 18.09.2013. - 21.09.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
Serotonergic receptors gene polymorphisms; metabolic syndrome
Sažetak
Introduction. Metabolic syndrome (MetS) appears frequently in schizophrenic patients treated with atypical antipsychotics. Its represents a serious health problem due to the increasing risk for the development of diabetes, hypertension and cardiovascular disorders. Although serotonergic receptors are molecular target for atypical antipsychotics, the association between variants of serotonergic receptors type 2A gene (HTR2A) and 2C gene (HTR2C) and MetS in patients treated with antipsychotics is unclear. The purpose of the study was to determine HTR2A and HTR2C polymorphisms and MetS in schizophrenic patients treated with antipsychotics with hypothesis that gene variants of serotonergic receptors are the risk factor for the development of the MetS. Methods. MetS was determined according to the NCEP/ATP III criteria. Waist circumference, triglycerides, high-density lipoprotein cholesterol, plasma glucose levels and blood pressure were assessed in unrelated Caucasians with schizophrenia (DSM-IV criteria) treated with olanzapine, risperidone or clozapine. The allele and genotype frequencies of HTR2A (102C/T ; rs6313), and HTR2C (-759C/T ; rs3813929) polymorphisms were determined in all patients. Results. The genotype frequencies of HTR2A (p = 0, 836 ; hi2 test) and HTR2C (p=0, 133 in female ; p=0, 963 in male patients) were independent on the occurence of MetS. The particular components of the MetS were not associated with the polymorphic variants of HTR2A and HTR2C. Conclusions. Results showed that variations at genes coding for serotonin receptors could not predict the development of MetS after antipsychotic treatment. Further studies are necessary to shed more light on the relationship between phenotypic measurement, metabolic side effects of antipsychotics and serotonin system in schizophrenic patients.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
098-0982522-2455 - Molekularna podloga i liječenje psihijatrijskih i stresom izazvanih poremećaja (Pivac, Nela, MZOS ) ( CroRIS)
098-0982522-2457 - Farmakogenomika i proteomika serotoninskog i kateholaminskog sustava (Muck-Šeler, Dorotea, MZOS ) ( CroRIS)
108-1083509-3511 - Nuspojave psihofarmaka u bolesnika s psihotičnim i afektivnim poremećajima (Uzun, Suzana, MZOS ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb
Profili:
Oliver Kozumplik
(autor)
Suzana Uzun
(autor)
Dorotea Muck-Šeler
(autor)
Maja Mustapić
(autor)
Nela Pivac
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus